Licenses and Other Agreements - Additional Information (Details) - USD ($)	1 Months Ended			3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jan. 31, 2020	Nov. 30, 2017	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2021
License Agreements [Line Items]
Research and development				$ 20,939,000	$ 27,366,000	$ 35,275,000	$ 49,686,000
Revenue				208,000	10,338,000	325,000	10,338,000
Purchase obligation, year 2022 through 2023								$ 14,000,000
Purchase obligation, year 2024								37,000,000
Purchase obligation, year 2025 through 2031								$ 48,000,000
Sublicense revenue
License Agreements [Line Items]
Revenue				200,000	10,300,000	300,000	10,300,000
Duke University
License Agreements [Line Items]
Aggregate royalties payment						200,000
Sale of licensed products or services						0
Fees payment						300,000
Nonroyalty payment received						1,000,000
Research and development				0	0	0	0
Wacker
License Agreements [Line Items]
Research and development				100,000	100,000	200,000	200,000
Viamet Pharmaceuticals Holdings, LLC
License Agreements [Line Items]
Research and development				0	0	0	0
License agreement upfront payment		$ 100,000
BioVectra
License Agreements [Line Items]
Research and development				$ 7,400,000	$ 0	7,400,000	$ 0
Achievement Of Clinical Development And Regulatory Milestones | Duke University
License Agreements [Line Items]
Potential milestones payment						2,200,000
Commercial Milestones | Duke University
License Agreements [Line Items]
Potential milestones payment						400,000
Commercial Milestones | Viamet Pharmaceuticals Holdings, LLC
License Agreements [Line Items]
Potential milestones payment		142,500,000
Achievement Of Certain Pre-Revenue Regulatory Milestones | Alfasigma S.p.A.
License Agreements [Line Items]
Potential milestones payment	$ 35,000,000
Potential milestones payment receivable	35,000,000
Achievement Of Certain Commercial Milestones And Tiered Royalty Payments On Net Sales | Alfasigma S.p.A.
License Agreements [Line Items]
Potential milestones payment	190,000,000
EMA Approval Of Application For Licensed Product | Alfasigma S.p.A.
License Agreements [Line Items]
Potential milestones payment receivable	10,000,000
Achievement Of Conditional Regulatory Approval From EMA | Alfasigma S.p.A.
License Agreements [Line Items]
Potential milestones payment receivable	12,500,000
Achievement Of Unconditional Regulatory Approval From EMA | Alfasigma S.p.A.
License Agreements [Line Items]
Potential milestones payment receivable	12,500,000
Achievement Of Certain Development And Intellectual Property Milestones | Viamet Pharmaceuticals Holdings, LLC
License Agreements [Line Items]
Potential milestones payment		$ 5,100,000
MedImmune Limited
License Agreements [Line Items]
Milestone payment			$ 3,000,000
MedImmune Limited | Achievement Of Clinical Development And Regulatory Milestones
License Agreements [Line Items]
Potential milestones payment			15,000,000
MedImmune Limited | Commercial Milestones
License Agreements [Line Items]
Aggregate royalties payment			$ 50,000,000
Alfasigma S.p.A.
License Agreements [Line Items]
Upfront payment from sublicense agreement	$ 20,000,000
Revenue						$ 11,157,000